Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-β deposition in Alzheimer’s disease

Fig. 2

Relationship between the blood expression levels of APH1B and neuroimaging biomarkers. The association of the blood expression levels of APH1B with entorhinal cortical thickness (a) and averaged cortical uptake of [18F] florbetapir PET (b) was represented in the scatter plot. In panel a, the orange and light blue dots denote data from ADNI and AddNeuroMed, respectively. The orange and light blue lines were obtained from a linear regression analysis in ADNI and AddNeuroMed, respectively. In panel b, the black dots denote data from ADNI and the dark blue line was obtained from a linear regression analysis. The gray zones around the lines indicate a 95% confidence interval. The transcript identifier for APH1B was 11720068_a_at in ADNI and ILMN_1767816 in AddNeuroMed, respectively. Abbreviation: ADNI, Alzheimer’s Disease Neuroimaging Initiative

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193